Speakers

Expand/Collapse

Jens Kaufmann
Managing Director
1717 Life Science Ventures

 

Day Two

Thursday 13th December 2018

11:55 am | Panel Discussion: Opening Up About Funding Challenges in Radiopharmaceuticals

11:35 am | Le Chatelier – Don’t Leave Anyone Behind During Radiopharmaceutical Development

Dale Ludwig
Chief Science & Technology Officer
Actinium Pharmaceuticals

Day Two

Thursday 13th December 2018

1:20 pm | Panel Discussion: Beyond PSMA – How Do We Realistically Identify New Targets to Take on with Radioligand Therapy

Chris Leamon
Indiana Site Head, Vice President of Discovery Research
Advanced Accelerator Applications

Day Two

Thursday 13th December 2018

1:20 pm | Panel Discussion: Beyond PSMA – How Do We Realistically Identify New Targets to Take on with Radioligand Therapy

1:00 pm | A Closer Look Into Ligand Targeted Radiotherapy

Maurizio Mariani
Head of Research & Development
Advanced Accelerator Applications

Day One

Thursday 13th December 2018

12:20 pm | Combining Radionuclides with a Comprehensive Array of Therapeutics for Improved Therapeutic Efficacy

Alison Armour
Founder
Curadh Pharmaceuticals

Day One

Thursday 13th December 2018

3:40 pm | Working Across Disciplines For More Effective Clinical Trials

Tom Christian Holm Anderson
PI 180 ºN, the Norwegian Nuclear Medicine Consortium Chief Radiochemist & Production Manager Centre for Nuclear Medicine & PET Department of Radiology
Haukeland University Hospital

 

Joao Osso
Section Head
International Atomic Energy Authority (IAEA)

Day Two

Thursday 13th December 2018

10:50 am | Current Radioisotope Stockpiles & Sourcing/Production Methods

Julian Kelly
Founder & Executive Director
Isoclide Medical

Day One

Thursday 13th December 2018

2:00 pm | 100% Assured Supply — 212Pb from Simple Generators Based on a Naturally-occuring Parent (228Th)

George Sgouros
Director, Radiological Physics Division, Professor of Radiology & Radiological Science
Johns Hopkins Medicine

Day One

Thursday 13th December 2018

4:00 pm | Radiopharmaceutical Therapy with Alpha Particle Emitters – Physics & Dosimetry Considerations

Alberto Andrighetto
Primo Technilogo
Istituto Nazionale di Fisica Nucleare

Day One

Thursday 13th December 2018

2:20 pm | The ISOLPHARM Project: New Production Method of High Specific Activity Beta-emitting Radionuclides

Almudena Rodriguez
Global Clinical Lead, Global Clinical Development Oncology
Merck KGaA

Day Two

Thursday 13th December 2018

2:50 pm | Synergies Between Radiopharmaceuticals & DNA-damage Response Inhibitors: Opportunities for Innovative Drug Development Paths

Cyril Berthet
Pharmaco-Imaging Unit Director
Oncodesign

Jason Hurt
Chief Medical Officer
Orano Med

Day One

Thursday 13th December 2018

12:40 pm | Radiopharmaceuticals & Clinical Oncology Trials

Izabela Tworowska
Chief Scientific Officer
RadioMedix Inc

Day Two

Thursday 13th December 2018

3:10 pm | Progress in Targeted Alpha-particle Therapies – Our Clinical Experience & Regulatory Perspective

Chris Behrenbruch
CEO
Telix Pharmaceuticals

Day One

Thursday 13th December 2018

10:00 am | Bringing Radiopharmaceuticals to Mainstream Oncology – The “Combo”

Dan Stevens
Chief Medical Officer
Theragnostics

Day Two

Thursday 13th December 2018

2:30 pm | PARP Targeted Auger Electrons: Nanometre Scale Radiotherapy

Greg Mullen
Chief Executive Officer
Theragnostics

Day Two

Thursday 13th December 2018

11:55 am | Panel Discussion: Opening Up About Funding Challenges in Radiopharmaceuticals

Oliver Sartor
Professor of Medicine Medical Director
Tulane Cancer Center; C. E. and Bernadine Laborde Professor of Cancer Research

Day One

Thursday 13th December 2018

3:40 pm | Lessons Learned From Radiopharmaceutical Trials in Prostate Cancer

Roland Turck
Managing Partner
TurckBio International Consulting

Day One

Thursday 13th December 2018

11:30 am | Radiopharmaceuticals – A Story of Success & Failure

Linjing Mu
Investigator
ETH Zürich

Day Two

Thursday 13th December 2018

9:50 am | Optimising Preclinical Testing For Fast Translation To The Clinic

Markus Luster
Chair of the Department of Nuclear Medicine
University Hospital Marburg

Day One

Thursday 13th December 2018

11:50 am | Novel Concepts in Radionuclide Therapy of Neuroendocrine Tumours

Rune Sundset
Director Of The Pre- Clinical Unit
University of Tromsø - The Arctic University of Norway (UiT)

Markus Luster

Chair of the Department of Nuclear Medicine

University Hospital Marburg

To find out more information on this year's event, including what topics these speakers will be discussing:

To find out more information on this year's event, including what topics these speakers will be discussing: